Back to catalogue
№ 049 18 filings · 2022-02-22 → 2026-07-27

ASTRAZENECA PLC

AZN
Health Care Share price 11,830p Market cap £186bn Overall fit 490 /1000

Solid quality growth healthcare with fair valuation and modest upside, but AI-receiver angle is limited (AZ is an AI user/spender, not seller) and operating leverage is moderate rather than the multi-bagger fixed-cost leverage the investor prefers. Good downside protection.

Fair value range 12,000p–14,600p Mid case · £206bn
Absolute upside +11% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • Clean disclosure and multi-year trackable Core EPS trajectory
  • Consistent delivery vs management guidance across 2022-2026
  • Broad pipeline reduces single-product risk to valuation
Limits the call
  • Large Reported-vs-Core gap requires interpretation of intangibles
  • $80bn 2030 revenue ambition depends on probabilistic pipeline delivery
Methodology

Forward P/E on FY2026 Core EPS with peer benchmarking

In one line · bull case

Diversified pharma leader with an unusually deep late-stage pipeline offsetting LoE pressures, trading at a fair-to-slightly-cheap multiple with visible earnings growth to 2030.

In one line · biggest risk

Failure of key Phase III readouts combined with accelerating LoE/China VBP pressure would leave the $80bn 2030 ambition unachievable and re-rate the shares lower.

Drivers
AI beneficiary 35 /100
AZ is an AI adopter (Modella acquisition, CSPC AI-peptide platform) but not a supplier to the AI value chain; proprietary data has training value but not monetised as a data platform.
Operating leverage 60 /100
82-84% Core Gross Margin with substantial fixed R&D and SG&A; incremental revenue drops through favourably but not with software-like multiplication of profit.
Earnings vs expectations 65 /100
Consistent meet/beat vs own guidance; FY 2024 upgraded twice; FY 2025 delivered at lower end of guidance range.
Growth momentum 65 /100
H1 2026 revenue +6% CER, Core Operating Profit +11%; multi-year record of mid-to-high single-digit revenue growth with double-digit EPS growth.
Moat 75 /100
Patent protection, industry-leading Oncology R&D scale, global commercial infrastructure and specialised Rare Disease franchise create durable competitive advantage.
Earnings quality 60 /100
Large gap between Reported ($3.60 H1 26) and Core ($5.21) EPS from Alexion amortisation; cash conversion moderate with significant capex expected up ~1/3 in FY 2026.
Management quality 75 /100
Pascal Soriot has delivered strong long-term transformation; consistent capital allocation and pipeline execution track record.
Cyclicality 15 /100
Defensive prescription healthcare with essential-medicine demand largely independent of macro cycle.
Leverage 40 /100
Net debt $26.9bn (~1.3-1.4x EBITDA), investment-grade A1/A+ ratings, comfortable coverage but not net cash.

ASTRAZENECA PLC (AZN) — Investment Research Note

Executive summary

AstraZeneca is a UK-listed global biopharmaceutical company focused on Oncology (~46% of revenue), Rare Disease (~16%), BioPharmaceuticals (CVRM ~20%, R&I ~15%), and Infectious Disease. The trajectory across the period is one of strong operational execution: reported USD revenue rose from ~$44.4bn (FY 2022) to $58.7bn (FY 2025), with Core EPS compounding from $6.66 to $9.16, driven by Oncology growth (Tagrisso, Imfinzi, Enhertu alliance, Calquence, Truqap) and expansion of the Rare Disease franchise following the 2021 Alexion deal 2026-02 FY 2025. The single most important valuation issue today is whether the pipeline (>20 high-value Phase III readouts due over next 18 months) can offset accelerating Loss-of-Exclusivity headwinds (Farxiga US LoE hit H1 2026: Farxiga -11% CER, US -17%) as the company pushes toward its $80bn 2030 ambition 2026-07 H1 2026.

Fair value estimate

Methodology: Forward P/E multiple applied to expected FY 2026 Core EPS, cross-checked against a growth-adjusted valuation implied by the $80bn 2030 revenue ambition.

  • FY 2025 Core EPS: $9.16. Company guides FY 2026 Core EPS to grow "low double-digit percentage" at CER → ~$10.10-$10.30 2026-07 H1 2026.
  • At an assumed USD/GBP ~1.27, FY 2026 Core EPS ≈ 795p–810p per share.
  • Peer forward P/E band: large-cap pharma with mid-single-digit revenue growth trades ~13-18x. AZ deserves the upper end given growth profile and pipeline density.
  • Applied range: 15x–18x forward Core EPS → fair value 12,000p – 14,600p per share.
  • Implied market cap range at 1.55bn shares: £186,000m – £226,300m
  • Midpoint fair value: ~13,300p / ~£206,150m
  • Current market cap: £189,828m; current price 12,110p
  • Upside to midpoint: ~+10%; range: -1% to +21%

Shares trade broadly in line with fair value — fair, with modest upside to central case. Not "priced for perfection" but not obviously cheap either.

Sector context

Confirmed sector: Health Care (ICB Super-sector: Health Care). AZ's quality is above sector average (best-in-class pipeline density, industry-leading Oncology franchise, ~34% Core Operating Margin), growth is meaningfully above peer average (mid-single-digit revenue growth vs. flat/low-single for many big pharma peers), and leverage is in line (net debt/EBITDA ~1.3-1.4x). Listed peers: Roche (SIX:ROG), Novartis (SIX:NOVN), GSK (LSE:GSK).

Investment thesis (3 bullets)

  • Late-stage pipeline momentum with catalysts: Six positive Phase III readouts in H1 2026 alone; 30 major-region approvals since Q4 2025 across Enhertu, Datroway, Imfinzi, Truqap, Baxfendy, Fasenra; >20 further high-value readouts due in next 18 months, providing multiple shots on goal to bridge to $80bn 2030 target 2026-07 H1 2026.
  • Oncology franchise breadth and durability: Oncology grew 15% CER in H1 2026, with Enhertu (+32%), Imfinzi (+29%), Calquence (+16%), Truqap (+41%) and Datroway (>6x) all growing double-digit — this diversification reduces single-medicine LoE risk vs. peers reliant on one or two blockbusters 2026-07 H1 2026.
  • Rare Disease franchise post-Alexion is delivering: Ultomiris (+14% CER H1 2026), Strensiq (+40%), Koselugo (+21%) drive Rare Disease growth of 11% CER, providing a durable, high-margin secondary growth engine 2026-07 H1 2026.

Key risks (3 bullets)

  • Cliff of LoE and China VBP pressure: Farxiga hit by US LoE in Q2 2026 (US -17% actual) and China VBP; Brilinta (-66% CER), roxadustat (-64% CER), Soliris biosimilar pressure — CVRM as a whole declined 12% CER in H1 2026, with several older products dropping faster than pipeline can offset 2026-07 H1 2026.
  • Pipeline setbacks are frequent and costly: CARDIO-TTRansform (Wainua in ATTR-CM) failed primary endpoint, EMERALD-2 (Imfinzi adjuvant HCC) failed, TMA-313 (Ultomiris HSCT-TMA) failed — even a stacked pipeline delivers negative surprises regularly, and $345m in intangible asset impairments recorded Q2 2026 2026-07 H1 2026. Historical: DUO-O Lynparza filings dropped globally 2025.
  • Rising legal and settlement liabilities: $220m University of Sheffield settlement, $181m Syntimmune additional damages, ongoing 340B litigation, PPI product liability (~$425m provision taken in 2023), CSPC $1.2bn upfront paid Q2 2026 with $3.5bn contingent — reported earnings persistently well below Core, and cash tax rising 2026-07 H1 2026; 2024-02 FY 2023.

Operating leverage

Core Gross Margin was 82% in H1 2026 and 84% in Q2 2026, indicating a genuinely fixed-cost-heavy P&L below the top line 2026-07 H1 2026. Core R&D at 23-24% of revenue and Core SG&A at 26-28% are largely fixed in the short term — R&D commitments are set by trial recruitment schedules, and SG&A is driven by launch investment plans made ahead of revenue. On a $30.7bn H1 2026 revenue base, Core Operating Profit was $10.5bn (34% margin). A 10-20% revenue beat above current guidance (i.e. incremental $3-6bn revenue at $58bn base) would drop through at approximately gross margin (~82-84%) less minimal incremental SG&A/R&D — plausibly $2.5-5bn incremental operating profit, adding ~15-30% to Core Operating Profit. That is meaningful but nowhere near the "multiple of profit" leverage of a software platform. There is no obvious step-change inflection (no fixed data-centre or single-site capacity to be filled); leverage is smooth and moderate rather than binary. However, high-margin new launches (Enhertu, Datroway, Baxfendy) do carry particularly favourable incremental economics because AZ leverages the existing global commercial infrastructure.

Value-trap signals

None identified. Revenue is growing mid-single-digit CER, dividend is being progressively increased (FY 2026 declared $3.30/share vs $3.20 prior year), balance sheet is comfortably investment-grade (Moody's A1 / S&P A+), management is delivering on guidance, and multiple pipeline catalysts are ahead rather than behind. LoE and China VBP pressures are real but well-flagged and being offset by launches — this is a growth stock temporarily digesting patent-cliff pressure, not a structural decliner.

Earnings vs. expectations

FY 2024: guidance issued at "high single-digit percentage" revenue growth was upgraded mid-year to "mid teens percentage" and delivered at 21% CER — a strong beat driven by COVID medicine tailwinds and Oncology outperformance 2024-07 H1 2024; 2025-02 FY 2024. FY 2025: guided low double-digit to low teens revenue growth at start of year, delivered 8% CER — met the lower end after China headwinds moderated growth. H1 2026: reconfirmed FY 2026 guidance of mid-to-high single-digit revenue growth, low double-digit Core EPS growth, tracking in line 2026-07 H1 2026. Pattern: consistent meet-to-beat versus own guidance, with the 2024 upgrade being the notable positive surprise.

Conviction

Rating: 4 (High).

Anchors: (1) very clean disclosure with reviewed interim/annual accounts; (2) Core EPS trajectory well-documented over 5 years and management guidance has proven directionally accurate; (3) valuation methodology (forward P/E vs. peers) is well-suited to a stable large-cap pharma with visible earnings.

Limits: (1) large gap between Reported and Core EPS (FY 2025 Reported $6.60 vs Core $9.16) — >$4bn in annual amortisation of intangibles from Alexion means Core is the right lens but adds interpretation risk; (2) $80bn 2030 ambition depends on pipeline delivery that is inherently probabilistic, and terminal-value assumptions carry more uncertainty than the near-term earnings guidance.

Filings consulted · 26

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-07-27Half Year Financial Report2026-07-27_9687613_half-year-financial-report.md0.90
  2. 2026-04-09Result OF Agm2026-04-09_9513414_result-of-agm.md0.30
  3. 2026-03-10Notice OF Agm2026-03-10_9467307_notice-of-agm.md0.30
  4. 2026-02-10Final Results2026-02-10_9422484_final-results.md0.85
  5. 2025-05-20Acquisition OF Esobiotec Completed2025-05-20_8886265_acquisition-of-esobiotec-completed.md0.49
  6. 2025-04-11Result OF Agm2025-04-11_8828014_result-of-agm.md0.20
  7. 2025-03-07Notice OF Agm2025-03-07_8769213_notice-of-agm.md0.20
  8. 2025-02-06Final Results2025-02-06_8724074_final-results.md0.65
  9. 2024-07-25Half Year Report2024-07-25_8329704_half-year-report.md0.41
  10. 2024-07-15Acquisition OF Amolyt Pharma Completed2024-07-15_8310018_acquisition-of-amolyt-pharma-completed.md0.34
  11. 2024-06-05Acquisition OF Fusion Completed2024-06-05_8242554_acquisition-of-fusion-completed.md0.34
  12. 2024-04-11Result OF Agm2024-04-11_8133896_result-of-agm.md0.14
  13. 2024-03-07Notice OF Agm2024-03-07_8076476_notice-of-agm.md0.14
  14. 2024-02-22Acquisition OF Gracell Completed2024-02-22_8051831_acquisition-of-gracell-completed.md0.34
  15. 2024-02-19Astrazeneca Completes Acquisition OF Icosavax2024-02-19_8045142_astrazeneca-completes-acquisition-of-icosavax.md0.34
  16. 2024-02-08Final Results2024-02-08_8027592_final-results.md0.45
  17. 2023-07-28Half Year Report2023-07-28_7660546_half-year-report.md0.23
  18. 2023-04-27Result OF Agm2023-04-27_7170_result-of-agm.md0.07
  19. 2023-03-22Notice OF Agm2023-03-22_7277702_notice-of-agm.md0.07
  20. 2023-02-09Final Results2023-02-09_7404050_final-results.md0.25
  21. 2023-01-16Acquisition OF Neogene Therapeutics Completed2023-01-16_7435948_acquisition-of-neogene-therapeutics-completed.md0.19
  22. 2022-08-11Acquisition OF Teneotwo Completed2022-08-11_7060447_acquisition-of-teneotwo-completed.md0.19
  23. 2022-07-29Half Year Report2022-07-29_6916543_half-year-report.md0.23
  24. 2022-04-29Result OF Agm2022-04-29_7139576_result-of-agm.md0.07
  25. 2022-03-23Notice OF Agm2022-03-23_7048866_notice-of-agm.md0.07
  26. 2022-02-22Chair Succession Planning Update And Annual Report2022-02-22_6887887_chair-succession-planning-update-and-annual-report.md0.24

This research note was authored by a large language model after reading 18 regulatory filings published between 2022-02-22 and 2026-07-27. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.